Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYL719 (Alpelisib) Window of Opportunity Study in Head and Neck Squamous Cell Carcinoma
NCT03138070Completed
- Start
- Oct 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of alpelisib in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Phospho-S6 (235/6) Expression. Started Oct 2017; status: completed.
02
Drugs
alpelisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03138070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138070.